• Epidemiology
• 37 min
  1. Assessment of obesity and classification of patients: historical perspectives and current practice

  • Prof. George Bray
• 40 min
  2. Epidemiology of obesity

  • Prof. Jacob Seidell
• Etiology and Causes
• 59 min
  3. Metabolic, adipose tissue and muscle predictors of obesity

  • Prof. Ian Macdonald
• 41 min
  4. Neural control of food intake and energy balance

  • Prof. Hans-Rudolf Berthoud
• 64 min
  5. Understanding obesity: genes and environment in the determination of body weight

  • Prof. Rudy Leibel
• 47 min
  6. Dietary determinants of obesity

  • Prof. Arne Astrup
• 42 min
  7. Physical inactivity as a determinant of obesity

  • Prof. Wim Saris
• 42 min
  8. Environmental causes of obesity: sociocultural, built environment and economic factors

  • Prof. Shiriki Kumanyika
• 29 min
  9. The developmental origins of obesity

  • Prof. David Barker
• Consequences of Obesity
• 46 min
  10. Obesity, dyslipoproteinemia and inflammation

  • Prof. Robert Eckel
• 23 min
  11. Pathophysiology and management of obesity related hypertension

  • Prof. Arya Sharma
• 22 min
  12. Disorders of overeating

  • Prof. Albert Stunkard
• 20 min
  13. Obesity, weight loss and health-related quality of life

  • Prof. Aila Rissanen
  • Dr. Jarmo Kaukua
• Treatment Options
• 44 min
  14. Lifestyle modification for weight control

  • Prof. Thomas Wadden
• 34 min
  15. Bariatric / obesity surgery

  • Prof. Henry Buchwald
• 48 min
  16. Can obesity be prevented in the current obesogenic environment?

  • Prof. Boyd Swinburn
• 28 min
  17. Pharmacotherapy for obesity: why it is needed

  • Prof. Joe Proietto
• 35 min
  18. Pharmacotherapy for obesity: hunger suppressors

  • Prof. Joe Proietto
• Latest Developments in the Field
• 60 min
  19. Body composition

  • Dr. Steven Heymsfield
• 56 min
  20. Adipose tissue metabolism and obesity

  • Dr. Max Lafontan
• 25 min
  21. Obesity, present and future therapies

  • Prof. Sir Stephen Bloom
• 42 min
  22. Energy expenditure in the lean and obese

  • Prof. Dale Schoeller
• 33 min
  23. Obesity and adiponectin

  • Prof. Philipp Scherer
• 44 min
  24. Ectopic fat: causes, consequences and treatment

  • Prof. Steven Smith
• 47 min
  25. Adipose-immune interactions in obesity

  • Dr. Vishwa Dixit
• 39 min
  26. Health benefits of intentional weight loss

  • Prof. Xavier Pi-Sunyer
• 39 min
  27. Childhood obesity: implications for current and future health

  • Prof. Peter T. Katzmarzyk
• 46 min
  28. The clinical assessment and management of child and adolescent obesity

  • Prof. Louise Baur
• Archived Lectures - These lectures may not cover the latest advances in the field
• 41 min
  29. Gastrointestinal peptides and food intake regulation

  • Prof. Sir Stephen Bloom
• 48 min
  30. Obesity and mortality: questions and controversy

  • Prof. David Allison
• 37 min
  31. Obesity, diabetes and the cluster of the metabolic syndrome

  • Prof. Peter Wilson
• 44 min
  32. New standards in weight management: recent and future drugs for the treatment of obesity

  • Prof. Luc Van Gaal
• 46 min
  33. Health economics of obesity: new insights

  • Dr. Anne Wolf
• 34 min
  34. Bariatric surgery: techniques and mechanisms of action

  • Prof. Walter Pories
• 39 min
  35. Childhood obesity: implications for future health

  • Prof. Peter T. Katzmarzyk
• 14 min
  36. Pharmacotherapy for obesity 1 - the need for pharmacotherapy in weight management

  • Prof. Joe Proietto
• 46 min
  37. Pharmacotherapy for obesity 2 - pharmacological agents in current use & under development

  • Prof. Joe Proietto

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Diabetes and CVD risk in Framingham cohort
3. Population attributable risk percent effects - men
4. Population attributable risk percent effects - women
5. Natural history of type 2 diabetes
6. Typical levels of insulin sensitivity
7. Assessment of insulin resistance
8. Increased CVD risk factors precede type 2 DM
9. Insulin resistance and atherosclerosis
10. Syndrome X
11. Metabolic traits cluster with hyperinsulinemia
12. Risk variables for a metabolic syndrome
13. Shared risk variables
14. CHD mortality and hyperinsulinemia
15. Diabetes and lipid extremes - men
16. Diabetes and lipid extremes - women
17. Adiposity and vascular inflammation
18. ATP III: the metabolic syndrome
19. ATP III: the metabolic syndrome since 2001
20. WHO: the metabolic syndrome
21. IDF: the metabolic syndrome
22. Age specific prevalence
23. Age-adjusted prevalence by race/ethnicity
24. Prevalence of the metabolic syndrome
25. Prevalence of coronary artery calcification (1)
26. Prevalence of coronary artery calcification (2)
27. Left ventricular mass according to insulin resistance
28. Mean CRP levels and the number of components
29. Metabolic syndrome risk factor sum - men
30. Metabolic syndrome risk factor sum - women
31. Metabolic syndrome outcomes - men
32. Metabolic syndrome outcomes - women
33. Metabolic syndrome factors age adjusted risk
34. Metabolic syndrome clustering
35. Prevalence of metabolic syndrome clustering
36. Metabolic syndrome clustering and relative risk
37. Age-adjusted hazard ratios for MI
38. Age and sex-adjusted hazard ratios
39. Risk for CHD events and new onset diabetes
40. Development of T2DM and CVD
41. Summary

Topics Covered

• The effect of diabetes, obesity and overweight on risks for heart disease
• Framingham Heart Study analyses
• The effects in men and women
• Metabolic studies of new diabetes
• Population studies
• Metabolic risk factor abnormalities generally precede the development of type 2 diabetes mellitus and contribute to the development of diabetes mellitus and accelerated atherosclerosis
• Differences in lipids and triglycerides
• Prevalence of the syndrome rises with age: increased risk of diabetes mellitus, subclinical vascular disease and clinical cardiovascular disease
• Risk for the development of vascular disease
• The European DECODE study
• The AFCAPS study
• Presence of the metabolic syndrome and increased levels of the inflammatory marker CRP may help to identify persons at higher risk of type 2 diabetes or vascular disease

Links

Series:

• Obesity

Categories:

• Clinical Practice

Therapeutic Areas:

• Cardiovascular & Metabolic

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Peter Wilson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.